Pipeline
Oncology
A002: HPV+ cancer
eTheRNA is developing an mRNA-based vaccine against HPV+ Head and neck cancer consisting of mRNA encoding for TriMix and E6/E7 antigens packaged in lipid nanoparticles administered intravenously. Currently, a candidate is being tested in preclinical studies.
A005: Renal cancer
eTheRNA, in collaboration with Frame Therapeutics, is developing a mRNA-based vaccine against renal cancer consisting of mRNA encoding for TriMix and frame shift neo-antigens packaged in lipid nanoparticles that will be administered intravenously.
View our Renal cancer factsheet for my detailed information.
A034: Solid Tumour
eTheRNA is developing mRNA-based products mimicking the action of oncolytic viruses. A mRNA-based approach has several advantages over oncolytic viruses:
- It's easier to regulate the mode of action of an mRNA-based product
- Side effects are expected to be less severe
- No viral antigens or anti-vector immunity
A single construct or a mix of naked or packaged mRNA is delivered directly into the tumour site giving direct access to the effector site of the therapy. This modality offers opportunities to develop products with cell-lytic, tumour microenvironment (TME) modulating mRNA. Preliminary in vitro and ex vivo experiments have provided promising anti-tumour responses in both the treated and untreated tumours suggesting a systemic response from a loco-regional delivery.
Other indications
Gastric Cancer– eTheRNA is currently seeking a partner to develop an mRNA-based autologous cell therapy for gastric cancer building upon prior clinical experience with mRNA in an ex vivo cancer setting.
Antigens in both the intranodal and intravenous products are interchangeable. By replacing the antigens, a range of oncology indications could be targeted. The technology is available for partnering and collaboration (see partnership page).
Infectious Disease
A006: SARS-CoV-2
eTheRNA is developing an mRNA vaccine for SARS-CoV-2 (COVID-19). It is composed of a spike protein and a daisy chain construct with conserved epitopes from structural and non-structural proteins.
A007: Malaria
eTheRNA is developing a mRNA immunotherapy for malaria in collaboration with Institut Pasteur. eTheRNA’s mRNA LNP platform is combined innovative antigens identified by Institut Pasteur to engineer an immunotherapy to be delivered via intramuscular administration.
A008: HIV
eTheRNA is developing an mRNA therapeutic vaccine for HIV in conjunction with its partner, ConServ (London, UK). eTheRNA’s mRNA LNP platform is combined with mRNA presenting novel, conserved immunogenic peptide sequences.
A010: Oncogenic viruses
eTheRNA is investigating potential prophylactic vaccines to protect against oncogenic viruses. The vaccines will be composed of eTheRNA’s LNP platform combined with innovative antigens identified by research partners.
eTheRNA's Goal
to commercialize mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases.
Oncology
To fight cancer, eTheRNA adopts multiple strategies including:
Immunostimulation: New, pioneering immunotherapies using proprietary TriMix mRNA technology to stimulate and educate dendritic cells to create a potent, durable T-cell-mediated immune response against tumors in specific cancer indications. Different routes of administration (intranodal and intravenous) and different sources of antigens (tumor-associated antigens, viral antigens and shared neoantigens) are being deployed in different combinations in multiple development programs.
Oncolysis & Tumour microenvironments (TME) modulation: An innovative mRNA mix that mimics the action of oncolytic viruses to induce immunogenic death of tumour cells and renders the tumour more susceptible towards the anti-tumour T cell response
The different approaches can be combined with each other and other classes of treatment interventions.
Infectious Diseases
To fight infectious diseases, eTheRNA is adapting its proprietary
TriMix technology to a product that can be administered intranasally or intramuscularly and lead to antigen-specific T-cell-mediated mucosal immunity. This new approach is being applied to vaccines to protect against upper respiratory tract viruses including SARS-CoV-2 (coronavirus).
Galileilaan 19, 2845 Niel, Belgium
Our Address
Our Mailbox
+32 3 369 17 40
Our Phone
© 2021 eTheRNA | Studio Hanswijk